Sai-Hong Ignatius Ou, MD PhD Health Science Clinical ProfessorChao Family Comprehensive Cancer Center University of California Irvine School of Medicine discusses these topics. NSCLC treatment options (circa February 2020 updated May 2020)Targeted therapy (FDA Approved indication)EGFR classical mutationsEGFR uncommon mutationsALK fusionROS1 fusionBRAF V600EMETex14+ NSCLC (Approved May 6, 2020)RET fusion (Approved May 8, 2020)Immunotherapy (FDA approved)Chemotherapy + IO for first-line treatment of Non-Sq NSCLC, Sq NSCLC, and SCLC. (PD-L1 expression agnostic)Single agent second line (PD-L1 expression agnostic)Chemotherapy (FDA approved)Chemo + anti-angiogenesis mAb (non-Sq NSCLC)Chemo + anti EGFR mAb (Sq NSCLC)Single agent + anti-angiogenesis mAb
Sponsors: